<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39457983</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Risk of Hepatitis B Virus Reactivation in COVID-19 Patients Receiving Immunosuppressive Treatment: A Prospective Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6032</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13206032</ELocationID><Abstract><AbstractText><b>Objectives:</b> This study aimed to evaluate the risk of hepatitis B virus reactivation (HBVr) in COVID-19 patients receiving immunosuppressive treatment, which has been insufficiently studied to date. Secondarily, we aimed to evaluate the seroprevalence of HBV infection in COVID-19 patients. <b>Methods:</b> We performed HBV screening on all Romanian adults hospitalized in four COVID-19 wards between October 2021 and September 2022. We enrolled patients with positive hepatitis B core antibody (anti-HBc) without protective hepatitis B surface antibody (anti-HBs), HBV treatment, or baseline immunosuppressive conditions, and we conducted a virological follow-up on these patients at 3 months. <b>Results:</b> We identified 333/835 (39.9%) anti-HBc-positive patients. Follow-up was performed for 13 patients with positive hepatitis B surface antigen (HBsAg) and 19 HBsAg-negative/anti-HBc-positive patients. Among those who received immunosuppressants, 4/23 (17.4%) patients experienced HBVr: 1 out of 8 (12.5%) HBsAg-positive patients (with 1.99 log increase in HBV DNA level) and 3 out of 15 (20%) HBsAg-negative/anti-HBc-positive patients (with a de novo detectable HBV DNA level). <b>Conclusions:</b> Administration of COVID-19 immunosuppressants may result in a significant risk of HBVr in co-infected patients. We recommend performing an HBV triple screen panel (HBsAg, anti-HBs, anti-HBc) for all COVID-19 patients receiving immunosuppressive treatment. HBV prophylaxis may be indicated in certain patients. Larger studies are needed in order to establish appropriate and cost-effective management for these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mihai</LastName><ForeName>Nicoleta</ForeName><Initials>N</Initials><Identifier Source="ORCID">0009-0005-3953-0767</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila', No 37, Dionisie Lupu, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Infectious Diseases 'Matei Bals', 1 Dr. Calistrat Grozovici, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olariu</LastName><ForeName>Mihaela Cristina</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-3442-2338</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila', No 37, Dionisie Lupu, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Infectious Diseases 'Matei Bals', 1 Dr. Calistrat Grozovici, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganea</LastName><ForeName>Oana-Alexandra</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila', No 37, Dionisie Lupu, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Infectious Diseases 'Matei Bals', 1 Dr. Calistrat Grozovici, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamescu</LastName><ForeName>Aida-Isabela</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases 'Matei Bals', 1 Dr. Calistrat Grozovici, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Dental Medicine, University of Medicine and Pharmacy 'Carol Davila', No 37, Dionisie Lupu, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molagic</LastName><ForeName>Violeta</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila', No 37, Dionisie Lupu, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Infectious Diseases 'Matei Bals', 1 Dr. Calistrat Grozovici, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aramă</LastName><ForeName>Ștefan Sorin</ForeName><Initials>ȘS</Initials><Identifier Source="ORCID">0000-0003-0019-934X</Identifier><AffiliationInfo><Affiliation>National Institute of Infectious Diseases 'Matei Bals', 1 Dr. Calistrat Grozovici, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Dental Medicine, University of Medicine and Pharmacy 'Carol Davila', No 37, Dionisie Lupu, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tilișcan</LastName><ForeName>Cătălin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases 'Matei Bals', 1 Dr. Calistrat Grozovici, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Dental Medicine, University of Medicine and Pharmacy 'Carol Davila', No 37, Dionisie Lupu, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aramă</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila', No 37, Dionisie Lupu, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Infectious Diseases 'Matei Bals', 1 Dr. Calistrat Grozovici, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">hepatitis B virus</Keyword><Keyword MajorTopicYN="N">immunosuppressive agents</Keyword><Keyword MajorTopicYN="N">reactivation</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39457983</ArticleId><ArticleId IdType="pmc">PMC11508539</ArticleId><ArticleId IdType="doi">10.3390/jcm13206032</ArticleId><ArticleId IdType="pii">jcm13206032</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  WHO COVID-19 Dashboard.  [(accessed on 10 September 2024)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Montazersaheb S., Khatibi S.M.H., Hejazi M.S., Tarhriz V., Farjami A., Sorbeni F.G., Farahzadi R., Ghasemnejad T. COVID-19 infection: An overview on cytokine storm and related interventions. Virol. J. 2022;19:92. doi: 10.1186/s12985-022-01814-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01814-1</ArticleId><ArticleId IdType="pmc">PMC9134144</ArticleId><ArticleId IdType="pubmed">35619180</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health  Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.  [(accessed on 8 August 2024)]; Available online:  https://www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf_NBK570371.pdf.</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Wang T., Cai Q., Sun L., Huang D., Zhou G., He Q., Wang F., Liu L., Chen J. Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection. Hepatol. Res. 2020;50:1211–1221. doi: 10.1111/hepr.13553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hepr.13553</ArticleId><ArticleId IdType="pmc">PMC7436737</ArticleId><ArticleId IdType="pubmed">32761993</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodríguez-Tajes S., Miralpeix A., Costa J., López-Suñé E., Laguno M., Pocurull A., Lens S., Mariño Z., Forns X. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J. Viral Hepat. 2021;28:89–94. doi: 10.1111/jvh.13410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvh.13410</ArticleId><ArticleId IdType="pmc">PMC7537127</ArticleId><ArticleId IdType="pubmed">32969557</ArticleId></ArticleIdList></Reference><Reference><Citation>Camarero J.G., Aranda E.B., Castro R.Q., Chumillas R.M.S., Vega L.A., Ruiz S.D., Manero N.G., Campo R.V., Plaza F.J. Hepatitis B and C screening in hospitalized patients with SARS-CoV-2 infection. Gastroenterol. Hepatol. 2022;45:256–264. doi: 10.1016/j.gastrohep.2021.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gastrohep.2021.09.002</ArticleId><ArticleId IdType="pmc">PMC8426135</ArticleId><ArticleId IdType="pubmed">34508809</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo H., Phan F., Bagatella M., Petrovski I., Nagendra V., Acharya P., Levy M., Prakoso E. Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19. Eur. J. Clin. Microbiol. Infect. Dis. 2023;42:799–801. doi: 10.1007/s10096-023-04599-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-023-04599-5</ArticleId><ArticleId IdType="pmc">PMC10119519</ArticleId><ArticleId IdType="pubmed">37084117</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLachlan J.H., Cowie B.C. Hepatitis B virus epidemiology. CSH Perspect. Med. 2015;5:a021410. doi: 10.1101/cshperspect.a021410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a021410</ArticleId><ArticleId IdType="pmc">PMC4448582</ArticleId><ArticleId IdType="pubmed">25934461</ArticleId></ArticleIdList></Reference><Reference><Citation>Trickey A., Bivegete S., Duffell E., McNaughton A.L., Nerlander L., Walker J.G., Fraser H., Hickman M., Vickerman P., Brooks-Pollock E., et al. Estimating hepatitis B virus prevalence among key population groups for European Union and European Economic Area countries and the United Kingdom: A modelling study. BMC Infect. Dis. 2023;23:457. doi: 10.1186/s12879-023-08433-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08433-3</ArticleId><ArticleId IdType="pmc">PMC10331985</ArticleId><ArticleId IdType="pubmed">37430220</ArticleId></ArticleIdList></Reference><Reference><Citation>Conners E.E., Panagiotakopoulos L., Hofmeister M.G., Spradling P.R., Hagan L.M., Harris A.M., Rogers-Brown J.S., Wester C., Nelson N.P. Screening and testing for hepatitis B virus infection: CDC recommendations—United States, 2023. MMWR Recomm. Rep. 2023;72:1–25. doi: 10.15585/mmwr.rr7201a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.rr7201a1</ArticleId><ArticleId IdType="pmc">PMC9997714</ArticleId><ArticleId IdType="pubmed">36893044</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrillo R.P., Gish R., Falck-Ytter Y.T. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221–244.e3. doi: 10.1053/j.gastro.2014.10.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2014.10.038</ArticleId><ArticleId IdType="pubmed">25447852</ArticleId></ArticleIdList></Reference><Reference><Citation>Korean Association for the Study of the Liver (KASL) KASL clinical practice guidelines for management of chronic hepatitis B. Clin. Mol. Hepatol. 2019;25:93–159. doi: 10.3350/cmh.2019.1002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3350/cmh.2019.1002</ArticleId><ArticleId IdType="pmc">PMC6589848</ArticleId><ArticleId IdType="pubmed">31185710</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau G., Yu M.-L., Wong G., Thompson A., Ghazinian H., Hou J.-L., Piratvisuth T., Jia J.-D., Mizokami M., Cheng G., et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol. Int. 2021;15:1031–1048. doi: 10.1007/s12072-021-10239-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-021-10239-x</ArticleId><ArticleId IdType="pmc">PMC8382940</ArticleId><ArticleId IdType="pubmed">34427860</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrault N.A., Lok A.S.F., McMahon B.J., Chang K.-M., Hwang J.P., Jonas M.M., Brown R.S., Jr., Bzowej N.H., Wong J.B. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599. doi: 10.1002/hep.29800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.29800</ArticleId><ArticleId IdType="pmc">PMC5975958</ArticleId><ArticleId IdType="pubmed">29405329</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiménez M.L., Garrido M.L., Cano M.C.F. Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis. Hepatology. 2022;75:765–766. doi: 10.1002/hep.32271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.32271</ArticleId><ArticleId IdType="pmc">PMC9015477</ArticleId><ArticleId IdType="pubmed">34888903</ArticleId></ArticleIdList></Reference><Reference><Citation>Giugliano L., Pinon M., Calvo P.L. COVID-19 as a trigger of acute-on-chronic hepatitis B presenting with undetectable INR due to hypercoagulability in a 16-year-old girl. Pediatr. Infect. Dis. J. 2023;42:143–145. doi: 10.1097/INF.0000000000003771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003771</ArticleId><ArticleId IdType="pmc">PMC9838603</ArticleId><ArticleId IdType="pubmed">36638401</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Wang S., Du M., Liu M., Liu Y., He Y. Patients with COVID-19 and HBV coinfection are at risk of poor prognosis. Infect. Dis. Ther. 2022;11:1229–1242. doi: 10.1007/s40121-022-00638-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-022-00638-4</ArticleId><ArticleId IdType="pmc">PMC9038996</ArticleId><ArticleId IdType="pubmed">35471766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastroianni A., Greco S., Chidichimo L., Mauro M.V., Urso F., Vangeli V. Antiviral prophylaxis for hepatitis B virus in COVID-19 patients treated with immunosuppressive drug therapy. Antivir. Ther. 2022;27:13596535211067602. doi: 10.1177/13596535211067602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13596535211067602</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y.-F., Yu W.-J., Jiang Y.-H., Chen Y., Zhang B., Zhen R.-B., Zhang J.-T., Wang Y.-P., Li Q., Xu F., et al. COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: A case report. World J. Clin. Cases. 2021;9:5266–5269. doi: 10.12998/wjcc.v9.i19.5266.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v9.i19.5266</ArticleId><ArticleId IdType="pmc">PMC8283611</ArticleId><ArticleId IdType="pubmed">34307577</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagnelli C., Montella L., Grimaldi P., Pisaturo M., Alessio L., De Pascalis S., Sagnelli E., Coppola N. COVID-19 as another trigger for HBV reactivation: Clinical case and review of literature. Pathogens. 2022;11:816. doi: 10.3390/pathogens11070816.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11070816</ArticleId><ArticleId IdType="pmc">PMC9318431</ArticleId><ArticleId IdType="pubmed">35890060</ArticleId></ArticleIdList></Reference><Reference><Citation>Braimakis I., Vasileiadi S., Trifylli E.-M., Papadopoulos N., Deutsch M. Can hepatitis B virus (HBV) reactivation result from a mild COVID-19 infection? Livers. 2023;3:347–353. doi: 10.3390/livers3030026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/livers3030026</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueredo C.J., Haider T., Guddati H., Massoumi H. A case of hepatitis B reactivation associated hepatitis after tocilizumab therapy in a patient with SARS-CoV-2 infection. Am. J. Gastroenterol. 2021;116:S1205–S1206. doi: 10.14309/01.ajg.0000785176.94176.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/01.ajg.0000785176.94176.27</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong G.L., Yuen B.W., Chan H.L., Tse Y., Yip T.C., Lam K.L., Lui G.C., Wong V.W. Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. Liver Int. 2019;39:271–279. doi: 10.1111/liv.13953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.13953</ArticleId><ArticleId IdType="pubmed">30179316</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong G.L.-H., Wong V.W.-S., Yuen B.W.-Y., Tse Y.-K., Yip T.C.-F., Luk H.W.-S., Lui G.C.-Y., Chan H.L.-Y. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. J. Hepatol. 2020;72:57–66. doi: 10.1016/j.jhep.2019.08.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2019.08.023</ArticleId><ArticleId IdType="pubmed">31499132</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L.-F., Mo Y.-Q., Jing J., Ma J.-D., Zheng D.-H., Dai L. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: A prospective clinical observation. Int. J. Rheum. Dis. 2017;20:859–869. doi: 10.1111/1756-185X.13010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.13010</ArticleId><ArticleId IdType="pubmed">28160426</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo M.H., Tseng C.-W., Lu M.-C., Tung C.-H., Tseng K.-C., Huang K.-Y., Lee C.-H., Lai N.-S. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing tocilizumab-containing treatment. Dig. Dis. Sci. 2021;66:4026–4234. doi: 10.1007/s10620-020-06725-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-020-06725-1</ArticleId><ArticleId IdType="pmc">PMC7775841</ArticleId><ArticleId IdType="pubmed">33387124</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M.-H., Liu C.-Y., Tsai C.-Y., Huang D.-F., Lin H.-Y., Lee M.-H., Huang Y.-H. Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. J. Infect. Dis. 2016;215:566–573. doi: 10.1093/infdis/jiw606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw606</ArticleId><ArticleId IdType="pubmed">28011918</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonneveld M.J., Murad S.D., van der Eijk A., de Man R. Fulminant liver failure due to hepatitis B reactivation during treatment with tocilizumab. ACG Case Rep. J. 2019;6:e00243. doi: 10.14309/crj.0000000000000243.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/crj.0000000000000243</ArticleId><ArticleId IdType="pmc">PMC6946203</ArticleId><ArticleId IdType="pubmed">32042838</ArticleId></ArticleIdList></Reference><Reference><Citation>Biehl A., Harinstein L., Brinker A., Glaser R., Muñoz M., Avigan M. A case series analysis of serious exacerbations of viral hepatitis and non-viral hepatic injuries in tocilizumab-treated patients. Liver Int. 2021;41:515–528. doi: 10.1111/liv.14766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14766</ArticleId><ArticleId IdType="pubmed">33320444</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell C., Andersson M.I., Ansari M.A., Moswela O., Misbah S.A., Klenerman P., Matthews P.C. Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following tocilizumab therapy: A systematic review to inform risk assessment in the COVID-19 era. Front. Med. 2021;8:706482. doi: 10.3389/fmed.2021.706482.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.706482</ArticleId><ArticleId IdType="pmc">PMC8417527</ArticleId><ArticleId IdType="pubmed">34490299</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip T.C.-F., Gill M., Wong G.L.-H., Liu K. Management of hepatitis B virus reactivation due to treatment of COVID-19. Hepatol. Int. 2022;16:257–268. doi: 10.1007/s12072-022-10306-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-022-10306-x</ArticleId><ArticleId IdType="pmc">PMC8889512</ArticleId><ArticleId IdType="pubmed">35235148</ArticleId></ArticleIdList></Reference><Reference><Citation>Harigai M., Winthrop K., Takeuchi T., Hsieh T.-Y., Chen Y.-M., Smolen J.S., Burmester G., Walls C., Wu W.-S., Dickson C., et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020;6:e001095. doi: 10.1136/rmdopen-2019-001095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2019-001095</ArticleId><ArticleId IdType="pmc">PMC7046961</ArticleId><ArticleId IdType="pubmed">32098857</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute of Diabetes and Digestive and Kidney Diseases  LiverTox: Clinical and Research Information on Drug-Induced Liver Injury—Anakinra.  [(accessed on 8 August 2024)]; Available online:  https://www.ncbi.nlm.nih.gov/books/NBK548615/</Citation></Reference><Reference><Citation>Barone M., Notarnicola A., Lopalco G., Viggiani M.T., Sebastiani F., Covelli M., Iannone F., Avolio A.W., Di Leo A., Cantarini L., et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology. 2015;62:40–46. doi: 10.1002/hep.27716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.27716</ArticleId><ArticleId IdType="pubmed">25613809</ArticleId></ArticleIdList></Reference><Reference><Citation>Pérez J.V., Chinesta J.R. Risk of hepatitis B reactivation associated with treatment against SARS-CoV-2 (COVID-19) with corticosteroids. Rev. Clin. Esp. 2020;220:535–536. doi: 10.1016/j.rceng.2020.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rceng.2020.04.006</ArticleId><ArticleId IdType="pmc">PMC7198170</ArticleId><ArticleId IdType="pubmed">32372768</ArticleId></ArticleIdList></Reference><Reference><Citation>Spera A.M. Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment. World J. Virol. 2022;11:275–282. doi: 10.5501/wjv.v11.i5.275.</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v11.i5.275</ArticleId><ArticleId IdType="pmc">PMC9523324</ArticleId><ArticleId IdType="pubmed">36188738</ArticleId></ArticleIdList></Reference><Reference><Citation>Satsangi S., Gupta N., Kodan P. Current and new drugs for COVID-19 treatment and its effects on the liver. J. Clin. Transl. Hepatol. 2021;9:436–446. doi: 10.14218/JCTH.2020.00174.</Citation><ArticleIdList><ArticleId IdType="doi">10.14218/JCTH.2020.00174</ArticleId><ArticleId IdType="pmc">PMC8237135</ArticleId><ArticleId IdType="pubmed">34221930</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong G.L., Chan H.L., Yuen B.W., Tse Y., Luk H.W., Yip T.C., Hui V.W., Liang L.Y., Lee H., Lui G.C., et al. The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. Liver Int. 2020;40:549–557. doi: 10.1111/liv.14330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14330</ArticleId><ArticleId IdType="pubmed">31845462</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>